Israel Englander Marker Therapeutics, Inc. Transaction History

Millennium Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.24 - $4.58 $40,636 - $775,485	169,320 New	169,320 $45,000
Q2 2022 Aug 15, 2022	SELL	$0.26 - $0.46 $36,487 - $64,554	-140,336 Reduced 60.37%	92,142 $30,000
Q1 2022 May 16, 2022	SELL	$0.37 - $1.0 $158,637 - $428,750	-428,750 Reduced 64.84%	232,478 $102,000
Q4 2021 Feb 14, 2022	SELL	$0.95 - $1.72 $56,703 - $102,663	-59,688 Reduced 8.28%	661,228 $628,000
Q3 2021 Nov 15, 2021	SELL	$1.68 - $2.88 $1.08 Million - $1.85 Million	-643,716 Reduced 47.17%	720,916 $1.22 Million
Q2 2021 Aug 16, 2021	BUY	$1.88 - $3.56 $2.15 Million - $4.07 Million	1,143,030 Added 515.8%	1,364,632 $3.81 Million
Q1 2021 May 17, 2021	BUY	$1.47 - $3.29 $295,824 - $662,082	201,241 Added 988.37%	221,602 $496,000
Q4 2020 Feb 16, 2021	BUY	$1.36 - $1.75 $27,690 - $35,631	20,361 New	20,361 $30,000
Q4 2019 Feb 14, 2020	SELL	$2.68 - $4.85 $126,209 - $228,401	-47,093 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$4.1 - $9.0 $193,081 - $423,837	47,093 New	47,093 $240,000
Q2 2019 Aug 14, 2019	SELL	$5.15 - $7.92 $914,531 - $1.41 Million	-177,579 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$5.1 - $6.71 $905,652 - $1.19 Million	177,579 New	177,579 $1.17 Million

475K

Ticker MRKR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,599,200
Market Cap $318M
Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufact...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.